Merck & Co. (NYSE:MRK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday. According to Zacks, “Merck’s third-quarter results were strong, with the company beating on all fronts and slightly raising both its sales and earnings outlook for the year. The latest FDA approval […]
